SCGN and type 2 diabetes mellitus: Pooled analysis using the random-effects model revealed significantly higher serum levels of HSP70 (SMD: 2.30, 95% CI: 1.13–3.46; p < 0.001) and secretagogin (SMD: 0.60, 95% CI: 0.19–1.01; p < 0.001) in T2D patients versus controls.